1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

12 Apr 2024
Admin
News Article

Strides Receives US FDA Approval for Fluoxetine Tabs 10 Mg & 20 Mg

Overview

Strides Pharma Science said that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Singapore, has received approval for fluoxetine tabs 10 mg and 20 mg, from the United States Food & Drug Administration (FDA).

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac tablets of Eli Lilly.

Global Market Size

Fluoxetine tablets has a market size of ~US$ 23.9 million as per IMS.
This approval further strengthens the company's presence in the fluoxetine portfolio, complementing the existing approval of fluoxetine capsules, which has a market size of US$106 million.
The fluoxetine tablets will be manufactured at the company’s facility in Puducherry.

ANDA Filings

The company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with US FDA, of which 245 ANDAs have been approved.
The company has set a target to launch ~ 60 new products over three years in the US.

Fluoxetine

Fluoxetine is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.
It is used for the treatment of major depressive disorder (MDD), obsessive–compulsive disorder (OCD), bulimia nervosa, panic disorder, with or without agoraphobia.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!